EA201290813A1 - Полиэпитопные конструкции и способы их получения и применения - Google Patents

Полиэпитопные конструкции и способы их получения и применения

Info

Publication number
EA201290813A1
EA201290813A1 EA201290813A EA201290813A EA201290813A1 EA 201290813 A1 EA201290813 A1 EA 201290813A1 EA 201290813 A EA201290813 A EA 201290813A EA 201290813 A EA201290813 A EA 201290813A EA 201290813 A1 EA201290813 A1 EA 201290813A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polyepitical
constructions
production
methods
application
Prior art date
Application number
EA201290813A
Other languages
English (en)
Other versions
EA025280B1 (ru
Inventor
Амир Максютов
Ринат Максютов
Анастасия Бакулина
Денис Антонец
Original Assignee
Максютов, Амир З.
Артемьев, Тимур
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Максютов, Амир З., Артемьев, Тимур filed Critical Максютов, Амир З.
Publication of EA201290813A1 publication Critical patent/EA201290813A1/ru
Publication of EA025280B1 publication Critical patent/EA025280B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к новым иммуногенным полиэпитопным конструкциям, содержащим CTL- и/или Th-эпитопы и оптимизированные спейсерные последовательности, улучшающие процессинг и презентацию указанных эпитопов, что обеспечивает индукцию интенсивного CD4+- и СD8+-специфичного Т-клеточного ответа и специфичных типов цитокинов, а также высокие уровни защиты и терапевтической активности.
EA201290813A 2010-03-09 2011-03-09 Полиэпитопные конструкции и способы их получения и применения EA025280B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31198110P 2010-03-09 2010-03-09
PCT/IB2011/000973 WO2011110953A2 (en) 2010-03-09 2011-03-09 Polyepitope constructs and methods for their preparation and use

Publications (2)

Publication Number Publication Date
EA201290813A1 true EA201290813A1 (ru) 2013-04-30
EA025280B1 EA025280B1 (ru) 2016-12-30

Family

ID=44563931

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290813A EA025280B1 (ru) 2010-03-09 2011-03-09 Полиэпитопные конструкции и способы их получения и применения

Country Status (4)

Country Link
US (1) US20130011424A1 (ru)
EP (1) EP2545071A2 (ru)
EA (1) EA025280B1 (ru)
WO (1) WO2011110953A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381242B2 (en) * 2011-03-11 2016-07-05 The Chemo—Sero—Therapeutic Research Institute Adjuvant composition containing citrulline
RU2520091C2 (ru) * 2012-08-16 2014-06-20 Общество с ограниченной ответственностью "АваксисБио" Способ стимуляции цитотоксического иммунного ответа против клеток опухолевой линии аденокарциномы молочной железы, экспрессирующих специфические антигены, с помощью дендритных клеток, трансфецированных полиэпитопной днк-конструкцией
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
RU2521506C1 (ru) * 2013-04-01 2014-06-27 Общество с ограниченной ответственностью "БиоМедТех" (ООО "БиоМедТех") Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью при раке молочной железы
CA2942501A1 (en) 2014-03-17 2015-09-24 Tapimmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
EP2959915A1 (en) 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
WO2016126611A1 (en) * 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
WO2017096247A1 (en) * 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
RU2684235C2 (ru) * 2016-11-29 2019-04-04 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) Полиэпитопная противоопухолевая вакцинная конструкция, содержащая эпитопы опухоль-ассоциированных антигенов, фармацевтическая композиция и ее применение для стимуляции специфического противоопухолевого иммунного ответа
KR20200008058A (ko) * 2017-06-16 2020-01-22 난트바이오 인코포레이티드 박테리아 백신(bacterial vaccine)
CA3077424A1 (en) * 2017-10-05 2019-04-11 Nantcell, Inc. Multivalent antigens stimulating th1 and th2
CN110904127A (zh) * 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
US20230145121A1 (en) * 2021-08-31 2023-05-11 Washington University Neoantigen vaccines for triple negative breast cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
WO1993008306A1 (en) 1991-10-22 1993-04-29 Symbicom Aktiebolag Improvement in borrelia burgdorferi diagnosis and prophylaxis
CA2072008C (en) 1989-12-22 2003-01-28 Renate Fuchs Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains
CA2104014C (en) 1991-02-15 2000-05-02 David E. Briles Structural gene of pneumococcal protein
CA2115554A1 (en) 1991-08-15 1993-03-04 Yves Lobet Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
JPH10507906A (ja) 1994-08-19 1998-08-04 ザ ジェネラル ホスピタル コーポレイション 遺伝子工学処理したブタ細胞
CA2384987A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
US6528060B1 (en) * 2000-03-16 2003-03-04 Genzyme Corporation Therapeutic compounds
WO2005089164A2 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CA2564538A1 (en) * 2004-04-22 2005-12-01 Oregon Health And Science University Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Also Published As

Publication number Publication date
US20130011424A1 (en) 2013-01-10
EA025280B1 (ru) 2016-12-30
WO2011110953A8 (en) 2012-05-10
WO2011110953A3 (en) 2012-07-05
EP2545071A2 (en) 2013-01-16
WO2011110953A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
EA201290813A1 (ru) Полиэпитопные конструкции и способы их получения и применения
EA201500659A1 (ru) Ацетилтрансферазы и их применение для получения каротиноидов
EA201890333A1 (ru) Противовирусные соединения
SG10201900948PA (en) Modified nucleotide linkers
EA201391597A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
EA201790781A2 (ru) Противовирусные соединения
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
EA201790963A1 (ru) Противовирусные соединения
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX2018011791A (es) Compuestos para transduccion viral mejorada.
MX2013010170A (es) Moduladores heterociclicos de sintesis lipidica.
EA201400836A8 (ru) Получение дитерпена
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
EA201390689A1 (ru) Консенсусные антигены простаты, молекула нуклеиновой кислоты, кодирующая их, и вакцина, и использование, включающее их
EP4253534A3 (en) Alpha-amylase variants and polynucleotides encoding same
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EP3696265A3 (en) Lipase variants and polynucleotides encoding same
MX356647B (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
EA201591057A1 (ru) Штамм bifidobacterium animalis ssp. animalis
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201590747A1 (ru) Способы лечения с использованием аденовируса
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU